Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Viral Specific T-Lymphocytes for Refractory Viral Infections
NCT06909110Phase 2Recruiting
- Start
- Apr 2025
- Primary completion
- May 2029
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of virus-specific T cells in adenovirus infection, cytomegalovirus infection (CMV) and Epstein-Barr virus infection. Primary endpoints: Grade III-IV Acute Graft versus host disease and CTCAE Grade 4/5 Adverse Events. Started Apr 2025; status: recruiting.
02
Drugs
virus-specific T cells
03
Conditions
adenovirus infectioncytomegalovirus infection (CMV)Epstein-Barr virus infection
Beyond the preview
Go deeper on NCT06909110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06909110.